Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.
You may also be interested in...
Bausch & Lomb Sold To Valeant Pharmaceuticals For $8.7 Billion
In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.
Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.
Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.